Latest News
TGA approves a new medication for MS: Ofatumumab
- A new treatment for relapsing MS has been approved by the TGA in Australia
- Ofatumumab will be marketed under the trade name Kesimpta®
- This treatment is in the same class as the medication Ocrevus and reduces the number of certain B cells in the body
The...
Ozanimod (Zeposia®) approved for PBS listing for relapsing remitting MS
Today (1 March, 2021) the Federal Health Minister, the Hon Greg Hunt MP announced the listing of ozanimod (Zeposia®) for the treatment of relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).
Zeposia was approved for treatment of relapsing forms of MS in Australia by...
MS Australia and MS Research Australia Facebook Pages Restricted
New book 'Growing Up Disabled in Australia' released today!
Edited by writer and appearance advocate, Carly Findlay, 'Growing Up Disabled in Australia' is a rich collection of writing from those negotiating disability in their lives – a group whose voices are not heard often enough:
‘My body and its place in the world seemed...
$2.9 million in funding awarded to new MS research projects
- MS Research Australia has awarded $2.9 million in new MS research grants commencing in January 2021.
- Thanks to the generosity of our supporters in The May 50K, we were able to award grants to all fundable applications in 2020.
- The 20 new projects target MS Research...
Season’s greetings from our Board President
This year has been a tough year for many and the stress and anxiety of living through the pandemic has been particularly difficult for many people living with MS. I know many of you will be glad to see 2020 draw to a close and are feeling optimistic about what 2021 might bring.
The MS International Federation wants to hear from you!
Submit a story about your support network for #WorldMSDay 2021.
MSIF is gathering global stories. We would love to see lots of tales with an Australian flavour/context and which tap into the #MSConnections theme and the 2021 Australian friends & family sub-theme.
Here’...
MS Australia announces the appointment of new CEO
Updated advice for persons with multiple sclerosis and related disorders regarding the COVID-19 pandemic
Background
Since December 2019 following cases emerging in and around Wuhan, China most regions of the world have now experienced cases of a novel respiratory illness (COVID-19) caused by a new coronavirus which has been identified as SARS-CoV-...
MS treatment announcement from PBAC
The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Australian Government about the medicines for subsidy through the Pharmaceutical Benefits Scheme (PBS).
At an “out-of-session” meeting in September 2020, the Pharmaceutical Benefits Advisory Committee (PBAC...
Australian Government approves PBS listing of Siponimod (brand name Mayzent®) for secondary progressive MS.
Yesterday (25 October, 2020) the Federal Health Minister, the Hon Greg Hunt MP announced the listing of siponimod (Mayzent) for the treatment of secondary progressive MS (SPMS) on the Pharmaceutical Benefits Scheme (PBS), from 1 November, 2020.
The Federal Health Minister’s media release...
#WhyWeCare – National Carers Week 2020
(Pictured: The Veronicas, Lisa & Jess Origliasso, who care for their mum, Colleen.)